Home Alzheimer’s Disease Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal...

Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer Symposium

The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.

In an interview with CancerNetwork®, Satya Das, MD, MSCI, assistant professor of Medicine in the department of Medicine in the division of Hematology/Oncology at Vanderbilt University Medical Center, spoke about the research he is most excited to see presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.

Transcription:

I’m a basically a [gastrointestinal] oncologist and I focus on neuroendocrine tumors…and also drug development. I think the things that interest me most pertain to those 2 areas. Particularly with regards to neuroendocrine tumors, I think the role for immunotherapy and the higher-grade neuroendocrine cancers is something that’s still actively being developed. There [are] some interesting data…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments